Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | TERT | O14746 | 3/20 | 0.41 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25820102 | 0.97 | NCF1 (0.41) | NCF1TERTIP6K1KDM4EMEN1 | |
| SCHEMBL25821152 | 0.90 | NCF1 (0.47) | NCF1KDM4EMEN1ALDH1A1GAA | |
| SCHEMBL25820175 | 0.89 | KMT2A (0.49) | NCF1KDM4EMEN1ALDH1A1GAA | |
| SCHEMBL24003941 | 0.84 | NCF1 (0.49) | NCF1TERTIP6K1MAP4K4 | |
| SCHEMBL25820144 | 0.82 | NPSR1 (0.48) | KDM4EMEN1ALDH1A1GAAMAPT | |
| SCHEMBL25820157 | 0.81 | TSHR (0.35) | — | |
| SCHEMBL25821159 | 0.81 | DPP4 (0.34) | NCF1ALDH1A1ALOX15MAPK1 | |
| SCHEMBL25821148 | 0.81 | MAPT (0.34) | NCF1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL25820145 | 0.81 | SYK (0.38) | NCF1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL25820104 | 0.80 | IP6K1 (0.48) | TERTIP6K1KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | NCF1 1223/4885TERT 4091/4885IP6K1 186/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | NCF1 1002/4885TERT 3883/4885IP6K1 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.